Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mitofusin 2, a mitochondria-ER tethering protein, facilitates osteoclastogenesis by regulating the calcium-calcineurin-NFATc1 axis.

Jung S, Kwon JO, Kim MK, Song MK, Kim B, Lee ZH, Kim HH.

Biochem Biophys Res Commun. 2019 Aug 13;516(1):202-208. doi: 10.1016/j.bbrc.2019.06.017. Epub 2019 Jun 14.

PMID:
31204051
2.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
3.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

4.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

6.

Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.

Yamashita T, Uehara S, Udagawa N, Li F, Kadota S, Esumi H, Kobayashi Y, Takahashi N.

PLoS One. 2014 Jan 17;9(1):e85878. doi: 10.1371/journal.pone.0085878. eCollection 2014.

7.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
8.

CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.

Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.

Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011. Epub 2015 Jun 21.

PMID:
26103094
9.

Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.

Ha H, Shim KS, Kim T, Lee CJ, Park JH, Kim HS, Ma JY.

BMC Complement Altern Med. 2014 Sep 23;14:352. doi: 10.1186/1472-6882-14-352.

11.

Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway.

Park KH, Park B, Yoon DS, Kwon SH, Shin DM, Lee JW, Lee HG, Shim JH, Park JH, Lee JM.

Cell Commun Signal. 2013 Oct 2;11:74. doi: 10.1186/1478-811X-11-74.

12.

Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.

Jules J, Zhang P, Ashley JW, Wei S, Shi Z, Liu J, Michalek SM, Feng X.

J Biol Chem. 2012 May 4;287(19):15728-38. doi: 10.1074/jbc.M111.296228. Epub 2012 Mar 13.

13.

Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.

Kim JY, Cheon YH, Oh HM, Rho MC, Erkhembaatar M, Kim MS, Lee CH, Kim JJ, Choi MK, Yoon KH, Lee MS, Oh J.

Bone. 2014 Mar;60:104-11. doi: 10.1016/j.bone.2013.12.013. Epub 2013 Dec 17.

PMID:
24361669
14.

Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.

Murakami A, Matsuda M, Harada Y, Hirata M.

J Biol Chem. 2017 May 12;292(19):7994-8006. doi: 10.1074/jbc.M117.784777. Epub 2017 Mar 24.

15.

Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.

Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, Kim N.

J Immunol. 2012 Jan 1;188(1):163-9. doi: 10.4049/jimmunol.1101254. Epub 2011 Nov 30.

16.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
17.

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.

Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, Lee HK, Yang YM.

PLoS One. 2016 Jul 22;11(7):e0159891. doi: 10.1371/journal.pone.0159891. eCollection 2016.

18.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

PMID:
19828731
19.

Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice.

Park SH, Kim JY, Cheon YH, Baek JM, Ahn SJ, Yoon KH, Lee MS, Oh J.

Phytother Res. 2016 Apr;30(4):604-12. doi: 10.1002/ptr.5565. Epub 2016 Jan 20.

PMID:
26792397
20.

Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.

Kim WS, Kim HJ, Lee ZH, Lee Y, Kim HH.

Exp Cell Res. 2013 Feb 15;319(4):436-46. doi: 10.1016/j.yexcr.2012.12.004. Epub 2012 Dec 12.

PMID:
23246654

Supplemental Content

Support Center